Lyell Immunopharma, Inc. (LYEL) is a biotechnology company headquartered in South San Francisco, California. Established in 2017, it aims to develop curative cell-based immunotherapies that eliminate cancer and other serious diseases.
Lyell Immunopharma is committed to unlocking the full potential of cell therapy by solving the fundamental challenges that impact the effectiveness of these treatments. With a robust and collaborative team comprising scientists, clinical and regulatory professionals, and a dedicated manufacturing team, the company extensively leverages cutting-edge technologies to make discoveries and advancements that can provide more effective treatment options for patients.
The company's primary focus lies in harnessing the power of T cells, known as the body's main soldiers in the immune fight against cancer. Lyell Immunopharma aims to utilize these cells to create transformative therapies that can tackle even the most challenging types of disease. Their approach involves carefully programming the T cells to manage their state of activation, memory, resilience, and metabolism, ultimately engineering them to beat various diseases, including haematological cancers, solid tumours, and other prevalent malignancies.
Lyell Immunopharma has a substantial portfolio, including the development pipeline of engineered T cell product candidates. Their flagship products include CAR-T and TCR-T programs designed to eradicate tumours and provide therapeutic immune response in the body.
Additionally, Lyell is an advocate for industry collaboration. The company has entered into several strategic partnerships with well-established oncology-focused firms, aiming to accelerate the progress in immune cell therapies with the potential to influence cancer care profoundly.
Lyell Immunopharma has made it clear that its primary goal is to see the day when cancer will be a treatable condition. By continually being at the forefront of research and innovation, and by deploying cutting-edge T-cell technologies, Lyell ensures that they stay at the helm of the biotech industry, progressively bringing the world closer to effective cancer treatment and care.